Evolugate Improves DNA-Plasmid Production, Ready To Impact COVID-19 Vaccines Manufacturing Throughput (PR Newswire)

Evolugate Improves DNA-Plasmid Production, Ready To Impact COVID-19 Vaccines Manufacturing Throughput

UF startup Evolugate, LLC, a Gainesville-based biotech company, has demonstrated that its proprietary technology can be used to improve the throughput of plasmid DNA manufacturing. Plasmids are essential for nucleic acid-based vaccines and gene therapies. Efficient plasmid production represents a significant bottleneck in the large-scale manufacture of several Covid-19 vaccines.

Plasmids are mass produced in bacteria and Evolugate has demonstrated the ability to increase plasmid production from 2-7 fold in two different strains of bacteria. One is a proprietary strain currently under development in-house and the other is a common, commercially used strain.

Learn more about Evolugate Improves DNA-Plasmid Production, Ready To Impact COVID-19 Vaccines Manufacturing Throughput.
Related news Evolugate Takes Up the Challenge of Boosting Host Cells Used to Manufacture COVID-19 Vaccines.
X